[HTML][HTML] The academic, economic and societal impacts of Open Access: an evidence-based review
Abstract Ongoing debates surrounding Open Access to the scholarly literature are
multifaceted and complicated by disparate and often polarised viewpoints from engaged …
multifaceted and complicated by disparate and often polarised viewpoints from engaged …
Comment: compulsory licensing of patented pharmaceutical inventions: evaluating the options
JH Reichman - Journal of Law, Medicine & Ethics, 2009 - cambridge.org
Few topics in international intellectual property law have been as controversial in recent
years as the one we are about to examine. In the 1980s and early 1990s, a Diplomatic …
years as the one we are about to examine. In the 1980s and early 1990s, a Diplomatic …
[图书][B] Private rights and public problems: The global economics of intellectual property in the 21st century
KE Maskus - 2012 - books.google.com
Consumers constantly confront intellectual property rights (IPRs) every day, from their
morning cup of Starbucks coffee to the Intel chip on their computer at work. Intellectual …
morning cup of Starbucks coffee to the Intel chip on their computer at work. Intellectual …
[HTML][HTML] Intellectual property in the twenty-first century: will the developing countries lead or follow?
JH Reichman - Houston law review/University of Houston, 2009 - ncbi.nlm.nih.gov
Developing countries, particularly the BRIC countries of Brazil, Russia, India, and China,
should accommodate their national systems of innovation to the worldwide intellectual …
should accommodate their national systems of innovation to the worldwide intellectual …
Value‐based differential pricing: Efficient prices for drugs in a global context
P Danzon, A Towse, J Mestre‐Ferrandiz - Health economics, 2015 - Wiley Online Library
This paper analyzes pharmaceutical pricing between and within countries to achieve
second‐best static and dynamic efficiency. We distinguish countries with and without …
second‐best static and dynamic efficiency. We distinguish countries with and without …
Pharmaceutical pricing in emerging markets: effects of income, competition, and procurement
PM Danzon, AW Mulcahy, AK Towse - Health economics, 2015 - Wiley Online Library
This paper analyzes determinants of ex‐manufacturer prices for originator and generic
drugs across countries. We focus on drugs to treat HIV/AIDS, TB, and malaria in middle and …
drugs across countries. We focus on drugs to treat HIV/AIDS, TB, and malaria in middle and …
The US proposal for an intellectual property chapter in the Trans-Pacific Partnership Agreement
SM Flynn, B Baker, M Kaminski, J Koo - Am. U. Int'l L. Rev., 2012 - HeinOnline
THE US PROPOSAL FOR AN INTELLECTUAL PROPERTY CHAPTER IN THE TRANS-PACIFIC
PARTNERSHIP AGREEMENT* Page 1 THE US PROPOSAL FOR AN INTELLECTUAL …
PARTNERSHIP AGREEMENT* Page 1 THE US PROPOSAL FOR AN INTELLECTUAL …
[HTML][HTML] Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries
Objectives Seven years after the introduction of direct-acting antivirals (DAAs) for the
treatment of hepatitis C, high prices remain a barrier for treatment programs worldwide. This …
treatment of hepatitis C, high prices remain a barrier for treatment programs worldwide. This …
Sustainable financing of innovative therapies: a review of approaches
A Hollis - Pharmacoeconomics, 2016 - Springer
The process of innovation is inherently complex, and it occurs within an even more complex
institutional environment characterized by incomplete information, market power, and …
institutional environment characterized by incomplete information, market power, and …
Differential pricing of pharmaceuticals: theory, evidence and emerging issues
PM Danzon - PharmacoEconomics, 2018 - Springer
Differential pricing—manufacturers varying prices for on-patent pharmaceuticals across
markets—can, in theory, lead to increased patient access and improved research and …
markets—can, in theory, lead to increased patient access and improved research and …